[go: up one dir, main page]

Patel, 2023 - Google Patents

The immunobiology of B Lymphocytes in non-small cell lung cancer

Patel, 2023

View PDF
Document ID
8821471062217918788
Author
Patel A
Publication year

External Links

Snippet

Lung cancer is the second most diagnosed cancer, after breast cancer, worldwide. However, it is still the leading cause of cancer-specific mortality globally, contributing to 18% of all cancer-related deaths. Non-small cell lung cancer (NSCLC) makes up 85% of lung cancers …
Continue reading at etheses.bham.ac.uk (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Similar Documents

Publication Publication Date Title
Good et al. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Liu et al. Progenitor-like exhausted SPRY1+ CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
Lv et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment
Khodadoust et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
Au et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Autio et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
Pfister et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Cader et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
Sahin et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sklavenitis-Pistofidis et al. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Audia et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes
CN113645981A (en) Methods and compositions for treating cancer
Thomas et al. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis
Damuzzo et al. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab
Coffey et al. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
WO2017042394A1 (en) "immune checkpoint intervention" in cancer
Rubio et al. Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
Blum et al. Immune responses in checkpoint myocarditis across heart, blood and tumour
Hu-Lieskovan et al. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Wang et al. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wermke et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A* 02+ patients: a phase 1 trial
Song et al. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
Zhang et al. Complement receptor C5aR1 blockade reprograms tumor‐associated macrophages and synergizes with anti‐PD‐1 therapy in gastric cancer
Okla et al. Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells–is a new era coming?
Bai et al. Single-cell analysis technologies for immuno-oncology research: from mechanistic delineation to biomarker discovery